May 09, 2022
Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 02, 2022
Alkermes to Highlight Data Related to Psychiatry Portfolio at Upcoming Scientific Conferences During Mental Health Awareness Month
April 27, 2022
Alkermes plc Reports First Quarter 2022 Financial Results
Alkermes' Head of Human Resources Steve Schiavo reflects on our employees' commitment during the COVID-19 pandemic.
Learn more about our ongoing clinical development program for nemvaleukin alfa, our lead immuno-oncology candidate. The investigational IL-2 variant immunotherapy is currently being studied across
As the unmet medical need in oncology changes, Alkermes is using its R&D capabilities honed over 30 years of work on complex diseases to investigate a potential next breakthrough in cancer therapy.
Alkermes is focused on developing innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we apply our scientific expertise and proprietary technologies to develop products designed to make a meaningful difference in the way people manage their diseases. Beyond our scientific pursuits, we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and supporting policies that enable access to approved treatment options.